New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

CytoMed Therapeutics Limited (GDTC) vs Lexaria Bioscience Corp. (LEXX)

CytoMed Therapeutics Limited and Lexaria Bioscience Corp. are both Biotechnology companies. CytoMed Therapeutics Limited and Lexaria Bioscience Corp. are of similar size ($9.5M and $9.2M). Across the 7 metrics below, Lexaria Bioscience Corp. leads on 4 and CytoMed Therapeutics Limited on 3.

Valuation

Metric GDTC LEXX Biotechnology median
P/E n/m n/m 8.49
P/S — 12.30 8.56
P/B 0.51 1.53 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales — 5.63 8.00
Earnings yield (35.90%) (129.52%) (35.81%)
Free cash flow yield (0.43%) (112.89%) (25.41%)

Profitability

Metric GDTC LEXX Biotechnology median
Gross margin — 99.62% 70.18%
Operating margin — (1,683.06%) 0.00%
Net margin — (1,686.05%) 0.00%
Free cash flow margin — (1,494.56%) 0.00%
Return on equity — (162.60%) (51.58%)
Return on assets — (134.20%) (45.91%)
Return on invested capital — (662.56%) 0.00%

Growth

Metric GDTC LEXX Biotechnology median
Revenue growth (TTM) — 52.04% 7.20%
EPS growth (last fiscal year) (68.75%) (40.43%) 29.04%
Revenue growth, 5-year CAGR — 17.53% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric GDTC LEXX Biotechnology median
Debt to equity 80.30 0.00 0.00
Current ratio 2.64 10.60 4.79
Net debt to EBITDA 0.86 0.17 1.01

Dividend

Metric GDTC LEXX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GDTC LEXX Biotechnology median
Market cap 9.15m 9.46m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack